{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:02:22Z","timestamp":1780012942405,"version":"3.53.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca, The Netherlands","award":["2604937054"],"award-info":[{"award-number":["2604937054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47197-z","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:16:14Z","timestamp":1775672174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective clinical evaluation of cell-free DNA next generation sequencing in patients with suspected metastatic lung cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Christi M. J.","family":"Steendam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud W. J.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Atmodimedjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keetie C. J.","family":"van Loenhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"van \u2019t Westeinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessel E. J. J.","family":"Hanselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evert","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-5207","authenticated-orcid":false,"given":"Hendrikus Jan","family":"Dubbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"47197_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour, K. C. & Riely, G. J. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review. JAMA 322, 764\u2013774 (2019).","journal-title":"JAMA"},{"key":"47197_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok, T. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 31, 1056\u20131064 (2020).","journal-title":"Ann. Oncol."},{"key":"47197_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N Engl. J. Med."},{"key":"47197_CR4","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon, B. J. et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J. Clin. Oncol. 42, 3400\u20133409 (2024).","journal-title":"J. Clin. Oncol."},{"key":"47197_CR5","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv192\u2013iv237 (2018).","journal-title":"Ann. Oncol."},{"key":"47197_CR6","doi-asserted-by":"crossref","unstructured":"Koopman, B. et al. A nationwide study on the impact of routine testing for EGFR mutations in advanced NSCLC reveals distinct survival patterns based on EGFR mutation subclasses. Cancers (Basel) 13. (2021).","DOI":"10.3390\/cancers13143641"},{"key":"47197_CR7","doi-asserted-by":"publisher","first-page":"e0202865","DOI":"10.1371\/journal.pone.0202865","volume":"13","author":"DH Lee","year":"2018","unstructured":"Lee, D. H. et al. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS One. 13, e0202865 (2018).","journal-title":"PLoS One"},{"key":"47197_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-018-4023-4","volume":"18","author":"A Ryska","year":"2018","unstructured":"Ryska, A. et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer. 18, 269 (2018).","journal-title":"BMC Cancer"},{"key":"47197_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00401","volume":"3","author":"CMJ Steendam","year":"2019","unstructured":"Steendam, C. M. J. et al. Plasma cell-free DNA testing of patients with EGFR mutant non-small-cell lung cancer: Droplet digital PCR versus next-generation sequencing compared with tissue-based results. JCO Precis Oncol. 3, 1\u20139 (2019).","journal-title":"JCO Precis Oncol."},{"key":"47197_CR10","doi-asserted-by":"crossref","unstructured":"Steendam, C. M. J. et al. Plasma predictive features in treating EGFR-mutated non-small cell lung cancer. Cancers (Basel) 12. (2020).","DOI":"10.3390\/cancers12113179"},{"key":"47197_CR11","unstructured":"Nederland, Longkankerzorg. https:\/\/www.longkankernetwerk.nl\/ (2021)."},{"key":"47197_CR12","doi-asserted-by":"publisher","first-page":"114125","DOI":"10.1016\/j.ejca.2024.114125","volume":"205","author":"VD de Jager","year":"2024","unstructured":"de Jager, V. D. et al. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands. Eur. J. Cancer. 205, 114125 (2024).","journal-title":"Eur. J. Cancer"},{"key":"47197_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2022.04.001","volume":"167","author":"EMP Steeghs","year":"2022","unstructured":"Steeghs, E. M. P. et al. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer. 167, 87\u201397 (2022).","journal-title":"Lung Cancer"},{"key":"47197_CR14","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl. J. Med. 389, 2039\u20132051 (2023).","journal-title":"N Engl. J. Med."},{"key":"47197_CR15","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima, E. C. et al. FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res. 28, 1482\u20131486 (2022).","journal-title":"Clin. Cancer Res."},{"key":"47197_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","volume":"42","author":"M Molina-Arcas","year":"2024","unstructured":"Molina-Arcas, M. & Downward, J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell. 42, 338\u2013357 (2024).","journal-title":"Cancer Cell."},{"key":"47197_CR17","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo, C. et al. Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer. J. Thorac. Oncol. 16, 1647\u20131662 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"47197_CR18","unstructured":"Oncologie, M. Sotorasib als tweede- of hogerelijnsbehandeling van het irresectabel of gemetastaseerd niet-kleincellig longcarcinoom (NSCLC) met een KRAS-G12C-mutatie (commissie ter Beoordeling van Oncologische Middelen (BOM), 2023)."},{"key":"47197_CR19","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1016\/j.cllc.2020.11.007","volume":"22","author":"JG Bustamante Alvarez","year":"2021","unstructured":"Bustamante Alvarez, J. G. et al. Treatment of non-small-cell lung cancer based on circulating cell-free DNA and impact of variation Allele frequency. Clin. Lung Cancer. 22, e519\u2013e27 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"47197_CR20","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.critrevonc.2020.102978","volume":"151","author":"C Rolfo","year":"2020","unstructured":"Rolfo, C. et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the international society of liquid biopsy (ISLB). Crit. Rev. Oncol. Hematol. 151, 102978 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"47197_CR21","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jtho.2024.06.014","volume":"19","author":"SM Ernst","year":"2024","unstructured":"Ernst, S. M., von der Thusen, J. H., Dubbink, H. J. & Dingemans, A. C. Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated NSCLC treated with Sotorasib. J. Thorac. Oncol. 19, e29\u2013e30 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"47197_CR22","doi-asserted-by":"publisher","first-page":"107844","DOI":"10.1016\/j.lungcan.2024.107844","volume":"193","author":"SM Ernst","year":"2024","unstructured":"Ernst, S. M., van Marion, R., von der Thusen, J. H., Dubbink, H. J. & Dingemans, A. C. Exploring the use of circulating tumor DNA for mutational signature analysis. Lung Cancer. 193, 107844 (2024).","journal-title":"Lung Cancer"},{"key":"47197_CR23","doi-asserted-by":"publisher","first-page":"103966","DOI":"10.1016\/j.esmoop.2024.103966","volume":"9","author":"VD de Jager","year":"2024","unstructured":"de Jager, V. D. et al. Molecular tumor board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy. ESMO Open. 9, 103966 (2024).","journal-title":"ESMO Open."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47197-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47197-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47197-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:22:00Z","timestamp":1780010520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47197-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47197"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47197-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS: no conflict of interestRM: no conflict of interestPA: no conflict of interestLvD: no conflict of interestCL: no conflict of interestKL: no conflict of interestSW: no conflict of interestDD: Honoraria and advisory boards for MSD, Amgen, AstraZeneca, BMS, Roche, Pharmamar. (personel and institution)WH: no conflict of interestMP: received consulting Advisory Boards: Amgen, Eli Lilly, Janssen, Merck, Pfizer all paid to insituteEJ: no conflict of interestRS: no conflict of interestJT: no conflict of interestJA: A received institutional research grants from AstraZeneca, Danone, Genmab and consulting fees from AstraZeneca, MSD, Danone, CureVac and speakers fees from BMS, MSD, Eli-Lilly and has issued patents for allogenic tumor cell lysate, combination immune-oncology drug, biomarker for immunotherapy and unpaid leadership role as Treasurer of IASLC and board member of IMIG and stock options in AmpheraAD: has received institutional consulting fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi, Johnson&Johnson, Pfizer, Roche, Abbvie, Mirati and received institutional speaker fees from Amgen, Eli Lilly, Johnson&Johnson and institutional fees for IDMC from Roche, Takeda and institutional fees for steering committee participation from Roche, Eli Lilly, Amgen and unpaid leadership as chair EORTC lung cancer groupHD: received institutional grants from AstraZeneca, MSD and personal speaker fees from AstraZeneca, MSD, GSK, BMS, Johnson&Johnson, Roche, Illumina and institutional support for attending a meeting from OncoDNA and personal fees for Advisory boards from Astellas, Abbvie, AstraZeneca, Janssen, MSD and institutional equipment\/materials from Illumina, OncoDNA, HederaDx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Medical ethical committee of the Erasmus MC approved this study but waived the need for informed consent. However, patients provided local consent for use of their (anonymized) data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"16646"}}